Novomics Co., Ltd. (XKON: 283100)

Market Cap	3.59B
Revenue (ttm)	206.03M
Net Income (ttm)	-3.42B
Shares Out	6.53M
EPS (ttm)	-523.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	375.00 - 4,340.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Novomics

Novomics Co., Ltd. designs and develops genetic molecular diagnostics solutions. The company offers nProfiler1 Expansion Stomach Cancer Assay to analyze the gene expression profiles of stage II-III gastric cancer. It also provides nProfiler 2, a cancer variant assay; AI assisted digital pathology and auto sampling system; nProfiler, a breast cancer assay; nProfiler, a colon cancer assay; nProfiler, a rectal cancer assay; and nProfiler, a cOVID-19 detection kit. The company was formerly known as Novomics Meditech Co., Ltd. and changed its name t...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: Korea New Exchange
• Ticker Symbol: 283100

Financial Performance

In 2022, Novomics's revenue was 206.03 million, a decrease of -32.13% compared to the previous year's 303.57 million. Losses were -3.42 billion, -50.09% less than in 2021.